CellCarta

As I celebrate and reflect on the past four years at CellCarta - what a privilege it is to work for this company, in this industry, with the most amazing sponsors and with this fantastic team! 🧪🩷 As another visit to the Boston area wraps up today - the smile on my face is hard to remove and it is not just because of a visit to Fenway ⚾️ Next stop ... #ASCO #cellcarta #workanniversary #clinicaltrials #biomarkers

Early-stage programs move fast. Your CRO should move even faster. We understand your programs can't afford to wait for results or get tangled in the regulatory overhead built for late-stage programs. Our California laboratory (part of CellCarta 's global network) is uniquely positioned to support your early-stage programs. From assay development to pathologist-validated biomarker readouts, we deliver rapid turnaround times without sacrificing the scientific rigor you require to advance your programs. And when your program scales, so do we, with our global network of fully owned labs. What does your early-stage program need most right now: speed, scientific partnership, or specimen access? Learn more about how we can offer all three: https://bit.ly/4ddxsO8 #Biotech #AssayDevelopment #Biomarkers #EarlyStage #ClinicalDevelopment

A conversation with Carl June on what’s next for cell therapy Great to catch up again with Carl—one of the true pioneers behind CAR-T—during a recent discussion. Carl’s continued influence is unmistakable—recently named to the 2026 Forbes America’s Greatest Innovators list. In our conversation, we explored a question that’s top of mind for many of us: What does the rise of in vivo CAR technologies mean for the future of cell therapy? A few takeaways that stood out: • This is expansion, not replacement. In vivo CAR (LNPs, viral delivery) adds a powerful new modality—but ex vivo approaches aren’t going anywhere. Their ability to support deep engineering (gene edits, multiplexing) will remain critical, especially in solid tumors. • Different diseases, different “sweet spots.” Oncology, autoimmune disease, and even regenerative medicine will each favor different platforms depending on risk tolerance, delivery, and mechanism. • Autoimmune is the surprising frontier. Perhaps the most striking shift: CAR-T moving into autoimmune disease—with lower toxicity than expected and rapid clinical adoption. This wasn’t even feasible to trial in the U.S. just a few years ago. • The immune system is an orchestra. Beyond T cells, we’re seeing momentum across NK cells, macrophages, Tregs, and γδ T cells—each with distinct advantages in persistence, targeting, and scalability. • The “body as a bioreactor.” In vivo delivery opens the door to treating patients on demand, potentially transforming access and logistics. As the field moves away from a single dominant approach, CellCarta is building a comprehensive toolbox of modalities—because the future lies in precisely matching each tool to each disease. Always energizing to hear Carl connect where the field started to where it’s heading next. Our full conversation is coming soon—stay tuned so you don’t miss it.

Encouraging to see Enspyre presented at AACR. The combination of ultra-sensitive ctDNA detection, low input performance and dramatically reduced sequencing requirements has clear relevance for the next wave of liquid biopsy applications. Through CellCarta’s expanding strategic partnership with Biofidelity, we’re excited not only by the current opportunity, but also by the work in progress to bring Enspyre technology into MRD clinical applications as a CTA-ready solution.